Open AccessHormonal contraception with progestagen desogestrel in women with diffuse non-toxic goiter аnd autoimmune thyroiditis
Author(s) -
Galina Petrovna Pologoyko,
Maria Igorivna Yarmolinskaya,
Tatyana Mihajlovna Lekareva
Publication year - 2013
Publication title -
žurnalʺ akušerstva i ženskihʺ boleznej
Language(s) - English
Resource type - Journals
eISSN - 1684-0461
pISSN - 1683-9366
DOI - 10.17816/jowd62640-46
Subject(s) - desogestrel , medicine , endocrinology , thyroid , goiter , thyroiditis , hormone , triiodothyronine , autoimmune thyroiditis , thyroid peroxidase , population , physiology , family planning , research methodology , environmental health
The article represents influence of gestagen desogestrel on size and function of thyroid gland in women of reproductive age. Into the study we included 70 women who were prescribed gestagen desogestrel in a daily dose of 75 mg for a period of 12 months. All the patients were devided into two groups. The first group consisted of 20 women with diffuse nontoxic goiter, the second consisted of 30 women with autoimmune thyroiditis. Control group consisted of 20 women without thyroid gland pathology. Prior to therapy with desogestrel and after 12 month of treatment, serum levels of free triiodothyronine, free thyroxine and thyrotropin releasing hormone, thyroperoxidase antibodies were determined and thyroid gland sonigraphy was performed in all the patients. Obtained data show that gestagen desogestrel doesn’t influence the size and function of thyroid gland in healthy women and in patients with diffuse non-toxic goiter. In women with autoimmune thyroiditis implication of desogestrel significantly decreases blood levels of thyroperoxidase autoantibodies.